A small provision in the proposed House user fee package that would allow generic drug user fee waivers runs counter to the technical agreement negotiated by the FDA and industry to create the program.
A group of provider and professional associations is already urging adoption of the provision, though, because they believe it could provide an incentive for manufacturers to enter new markets and prevent drug shortages
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?